相关实验视频

Updated: Jul 26, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

诺普拉桑:一种新的竞争性酸阻塞剂

Erin St Onge¹, Bradley Phillips¹

¹Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

|June 16, 2023

概括

沃诺普拉桑是一种与竞争的酸阻塞剂,其疗效与*Helicobacter pylori*根除的质子抑制剂无差. 这种药物为胃肠道疾病提供了潜在的更安全,更有效的替代品.

科学领域:

胃肠病学胃肠病学
药理学药理学是指药理学的学科.

背景情况:

*Helicobacter pylori*感染是胃肠道疾病的常见原因之一.
目前的治疗指南建议使用质子抑制剂 (PPI) 进行*H. pylori*根除.
个人保护剂的局限性包括不良影响,药物相互作用和可变的耐受性.

研究的目的:

审查vonoprazan的安全性,疗效和耐受性.
评估诺普拉桑作为一种替代性抑制*H. pylori*感染的酸性药物.

主要方法:

在PubMed的文献搜索中使用关键词:vonoprazan,Voquezna,TAK-438,竞争性酸阻断剂,*H pylori*,胃肠道.
包括关于vonoprazan的药理学,药理动力学,疗效,安全性和耐受性的临床研究.

主要成果:

诺普拉桑通过在质子上与竞争来抑制胃酸分泌.
第三阶段试验表明,诺普拉桑在*H. pylori*根除方案中与PPI无差.
诺普拉桑在十二指肠治愈和减轻心烧症状方面表现出有效性,常见的副作用包括鼻炎和腹.

结论:

沃诺普拉桑是一种与竞争的酸阻断剂 (P-CAB),是PPI和H2RAs的安全有效替代品.
像vonoprazan这样的P-CABs在治疗*H. pylori*感染和其他胃肠道疾病方面可能具有优势.
进一步的研究可能会支持vonoprazan在临床实践中的作用,用于与酸有关的疾病.

关键词:

这就是H pylori.这里是TAK-43838的位置.这是一个非常独特的语音.在胃肠道上,胃肠道.具有竞争力的酸阻塞剂.这就是Vonoprazan.

更多相关视频

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...